Colonic Transit Time Validation Study (CTT)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The protocol described herein is designed to provide clinical evidence of the substantial equivalence of SmartPill GI Monitoring System (SP) to the Sitzmarks (Konsyl Pharmaceuticals, Easton, MD) radio-opaque markers (ROM). The trial will enroll symptomatic subjects who meet Rome III criteria (1) for chronic functional constipation.
| Condition |
|---|
|
Constipation |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | SmartPill Colonic Transit Time Validation Study in Patients With Chronic Constipation |
- Colonic Transit Time [ Time Frame: 4 days and 7 days ] [ Designated as safety issue: No ]
- Determine regional gut (gastric, small bowel, colonic) transit times [ Time Frame: continuous time measure until caspule elimination ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 210 |
| Study Start Date: | March 2009 |
| Estimated Study Completion Date: | June 2009 |
| Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Constipated
Adult subjects with functional constipation as define by Rome II criteria
|
Detailed Description:
The primary aim of this study is to assess the equivalence of SP to ROM through characterization of device agreement using SP cutoffs for colonic and whole gut transit (59hrs and 73 hrs respectively) derived from the above mentioned study. The cutoffs are derived from the 95th percentile of the healthy subjects in the study. Demonstration of agreement will also serve to validate these SP cutoffs. Device agreement will be evaluated by comparing the percentage of subjects identified with slow transit versus normal transit with SmartPill to the percentage of subjects identified with slow versus normal transit with ROM in the study population. The colonic transit time results will serve as the primary measure for slow versus normal transit for SmartPill. For ROM test we will employ the Metcalf protocol which provides a measure of whole gut transit to compare the SmartPill results to. Additionally, we will characterize gastric emptying and small bowel transit time of the SmartPill in this population. The SmartPill test will be administered simultaneously with ROM. A modified Metcalf procedure will be employed for characterization of slow transit by ROM.
The SmartPill GI Monitoring System offers an alternative non-invasive method for characterizing disorders of the stomach. The system consists of an ingestible capsule that houses sensors for pH, temperature, and pressure, a receiver for receiving and storing signals from the capsule, and software for displaying data on a personal computer. The capsule samples at regular intervals and transmits the sensed pH, pressure, and temperature data to a portable receiver worn by the subject. After test completion, the recorded data is downloaded to a personal computer for subsequent evaluation. This trial is for subjects 18 years of age to 80 years of age.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
patients with constipation referred to a tertiary motility center
Inclusion Criteria:
- Males and females between ages of 18-80 years of age with symptoms of chronic functional constipation for at least one year.
- Self reported bowel movement frequency of < 2 bowel movements/week for at least 3 of the last 6 months.
Presenting at least one of the following symptoms as defined by Rome III criteria
- Feeling of incomplete evacuation with > 25% of bowel movements
- Digital maneuvers with > 25% of bowel movements
- Hard stools with > 25% of bowel movements
- Feeling of blockage with > 25% of bowel movements
- Straining with > 25% of bowel movements
- Constipation, not abdominal pain, as the predominant symptom.
- Ability to stop laxatives, prokinetic agents, and narcotic analgesic agents 3 days prior to SP and ROM ingestion visit and during the study period.
- Ability to stop proton pump inhibitors for seven days and Histamine2 blockers for three days prior to and the day of SmartPill ingestion.
- No evidence of metabolic disease (hypothyroidism, uncontrolled diabetes, electrolyte imbalance).
A normal colonoscopy or barium enema within 5 years for individuals over 50 years of age.
-
Exclusion Criteria:
- Participation in the previous SmartPill Whole gut transit Study titled "Assessment of Whole Gut Transit Time Using the SmartPill Capsule: A Multicenter Study" Protocol Number 122205
- Previous history of bezoars.
- Prior GI surgery except for cholecystectomy, appendectomy, or Nissen fundoplication
- Any abdominal surgery within the past 3 months
- Known or history of inflammatory bowel disease
- History of diverticulitis, diverticular stricture, and other intestinal strictures
- Tobacco use within eight hours prior to capsule ingestion and during the initial 8 hour recording on Day 0 or the Ingestion visit.
- Alcohol use within eight hours prior to capsule ingestion and throughout the entire monitoring period (5 days).
- BMI > 40 kg/m2
- Allergies to components of the SmartBar (Appendix IX).
- Females of childbearing age who are not practicing birth control and/or are pregnant or lactating. (A urine pregnancy test will be performed on female subjects prior to capsule ingestion). Acceptable forms of birth control include oral contraceptives, double barrier method, and IUD cover and must be practiced from the time of enrollment until the time of release from the study.
- Cardiovascular, endocrine, renal, or other chronic disease likely to affect motility.
- Use of medical devices such as pacemakers, infusion pumps, or insulin pumps.
- Any contraindication to use of Fleets Enema.
- Uncontrolled diabetes with a hemoglobin A1C greater than 10%.
Severe dysphagia to food or pills
-
Contacts and Locations| Contact: Kelli Regan | 716-882-0701 ext 120 | kregan@smartpillcorp.com |
| Contact: Tracy Crawford | 716-882-0701 ext 124 | tcrawford@smartpillcorp.com |
| United States, Arizona | |
| University of Arizona Health and Sciences Ctr Southern Arizona VA HealthCare System | Withdrawn |
| Tucson, Arizona, United States, 85723 | |
| United States, California | |
| Cedars-Sinai Medical Center | Completed |
| Los Angeles, California, United States, 90048 | |
| United States, Iowa | |
| University of Iowa | Completed |
| Iowa City, Iowa, United States, 52242 | |
| United States, Kansas | |
| University of Kansas Med Center | Completed |
| Kansas City, Kansas, United States, 66160 | |
| United States, Massachusetts | |
| Massachusetts General Hospital | Completed |
| Boston, Massachusetts, United States, 02114 | |
| United States, Michigan | |
| University of Michigan Med Center | Recruiting |
| Ann Arbor, Michigan, United States, 48109 | |
| Contact: Lina Nahlawi 734-936-2761 lnahlawi@med.umich.edu | |
| Principal Investigator: Richard Saad, MD | |
| Jasper Clinic, Inc. | Completed |
| Kalamazoo, Michigan, United States, 49007 | |
| United States, Minnesota | |
| Mayo Clinic | Completed |
| Rochester, Minnesota, United States, 55905 | |
| United States, New York | |
| University of Buffalo VA Medical Center | Completed |
| Buffalo, New York, United States, 14215 | |
| United States, North Carolina | |
| University of North Carolina Medical Center | Completed |
| Chapel Hill, North Carolina, United States, 27516 | |
| Wake Forest University Medical Center | Completed |
| Winston Salem, North Carolina, United States, 27157 | |
| United States, Pennsylvania | |
| Temple University Medical Center | Completed |
| Philadelphia, Pennsylvania, United States, 19140 | |
| United Kingdom | |
| Queen Mary, University of London | Completed |
| London, United Kingdom | |
| Study Chair: | John R Semler, PHD | The SmartPill Corporation |
More Information
No publications provided by The SmartPill Corporation
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Jack Semler/Chief Technology Officer, The SmartPill Corporation |
| ClinicalTrials.gov Identifier: | NCT00857363 History of Changes |
| Other Study ID Numbers: | 120508 |
| Study First Received: | March 4, 2009 |
| Last Updated: | January 14, 2010 |
| Health Authority: | United States: Institutional Review Board United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Keywords provided by The SmartPill Corporation:
|
capsule constipation whole gut transit |
colonic transit gastric emptying small bowel transit |
Additional relevant MeSH terms:
|
Constipation Signs and Symptoms, Digestive Signs and Symptoms |
ClinicalTrials.gov processed this record on May 23, 2013